These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15193449)

  • 1. Deletion of 5q31 and 7q31 in patients with stable melphalan treated multiple myeloma.
    Amiel A; Yukla M; Yogev S; Manor Y; Fejgin MD; Lishner M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):84-7. PubMed ID: 15193449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion 5q31 in patients with stable, melphalan-treated multiple myeloma.
    Amiel A; Fridman K; Elis A; Gaber E; Manor Y; Fejgin M; Lishner M
    Cancer Genet Cytogenet; 1999 Aug; 113(1):45-8. PubMed ID: 10459345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
    Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
    Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
    Bigoni R; Cuneo A; Milani R; Cavazzini F; Bardi A; Roberti MG; Agostini P; della Porta M; Specchia G; Rigolin GM; Castoldi G
    Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome.
    Ishii Y; Hsiao HH; Sashida G; Ito Y; Miyazawa K; Kodama A; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Jun; 167(2):131-7. PubMed ID: 16737912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
    Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
    Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
    Cancer Genet Cytogenet; 2007 Jun; 175(2):125-31. PubMed ID: 17556068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-related myelodysplastic syndrome. Two cytogenetically unrelated abnormal clones in a patient with multiple myeloma.
    Abeliovich D; Yehuda O; Ben-Neriah S; Matzner Y
    Cancer Genet Cytogenet; 1993 Oct; 70(2):117-9. PubMed ID: 8242590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired PBPC collection in patients with myeloma after high-dose melphalan.
    Jansen J; Thompson J; Dugan M; Wiemann M; Hanks S; Greenspan A; Akard L
    Cytotherapy; 2004; 6(5):498-504. PubMed ID: 15512916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.
    Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Papadimitriou C; Sfikakis PP
    J Clin Oncol; 2005 Jul; 23(19):4381-9. PubMed ID: 15883412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y; Qin YW; Wang C; Yang J; Yan SK
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
    Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
    DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards.
    Souliotis VL; Dimopoulos MA; Sfikakis PP
    Clin Cancer Res; 2003 Oct; 9(12):4465-74. PubMed ID: 14555520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.